



NIRVANA ANNOUNCES DIRECTOR RESIGNATION

VANCOUVER, B.C. October 5, 2022 (NEWSFILE) - Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") announces that Effective immediately, Mr. Edward Lupton has resigned from his position as Director of the Nirvana board of directors. Mr. Lupton served as a director of the former Endocan Solutions Inc. since 2020. The Company would like to thank Mr. Lupton for his leadership during his tenure as Director which served the Company very well.

About Nirvana Life Sciences

Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelic space. Its business model combines the development of novel formulations for drug development with the development of laboratory space to support ongoing development and manufacturing. At Nirvana, we believe that psilocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities. For more information visit <https://nirvanalifescience.com/>

For further information:

Bruce Clark CEO

info@nirvanalifescience.com

Phone: 604-401-8100

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

